Literature DB >> 8663512

Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate.

M Fannon1, M A Nugent.   

Abstract

We have investigated the interaction of basic fibroblast growth factor (bFGF) with its receptors and heparan sulfate proteoglycans (HSPG). It has been suggested that in the absence of HSPG, cells are not able to bind bFGF or respond to treatment with bFGF. In our studies, Balb/c3T3 fibroblasts were treated with 50 mM sodium chlorate to completely inhibit (99%) sulfation of proteoglycans. We found that bFGF was able to bind, be internalized, and stimulate DNA synthesis in the absence of HSPG in a dose-dependent manner. bFGF bound to its receptors on chlorate-treated cells with a lower apparent affinity and no change in receptor number. To determine if this decreased affinity bFGF-receptor interaction is functional, we quantitatively analyzed bFGF internalization and stimulation of DNA synthesis in control and chlorate-treated cells. Endocytotic rate constants (ke) for chlorate-treated and control cells were ke = 0. 078 +/- 0.022 min-1 and ke = 0.043 +/- 0.012 min-1, respectively, suggesting that the process of bFGF internalization is not dramatically altered by HSPG. bFGF stimulated DNA synthesis to the same maximal level under both conditions, but chlorate-treated cells were significantly less responsive at low bFGF doses (approximately 10-fold increase in ED50). The differences observed for control and chlorate-treated cells in the dose-response curves for stimulation of DNA synthesis and receptor binding correlated directly, suggesting that receptors are equally capable of eliciting a mitogenic signal under both conditions. It is unlikely that these results are due to residual HSPG since heparinase (I and III) digestion of chlorate-treated cells had little effect. Although the presence of HSPG on the cell surface increases the affinity of bFGF for its receptors, our observations suggest that HSPG are not "absolutely" required for binding, internalization, or stimulation of mitogenic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663512     DOI: 10.1074/jbc.271.30.17949

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans.

Authors:  J C Davis; G Venkataraman; Z Shriver; P A Raj; R Sasisekharan
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

Review 2.  Heparan sulfate: growth control with a restricted sequence menu.

Authors:  J T Gallagher
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity.

Authors:  Alphonse I Arunkumar; Thallampuranam Krishnaswamy S Kumar; Karuppanan Muthusamy Kathir; Sampath Srisailam; Han-Min Wang; Philominathan Sagaya Theresa Leena; Ya-Hui Chi; Ho-Chz Chen; Chieh-Hsi Wu; Rong-Tsun Wu; Gu-Gang Chang; Ing-Ming Chiu; Chin Yu
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

4.  Effects of receptor clustering on ligand dissociation kinetics: theory and simulations.

Authors:  Manoj Gopalakrishnan; Kimberly Forsten-Williams; Matthew A Nugent; Uwe C Täuber
Journal:  Biophys J       Date:  2005-09-08       Impact factor: 4.033

5.  Endothelial cell capture of heparin-binding growth factors under flow.

Authors:  Bing Zhao; Changjiang Zhang; Kimberly Forsten-Williams; Jun Zhang; Michael Fannon
Journal:  PLoS Comput Biol       Date:  2010-10-28       Impact factor: 4.475

6.  Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.

Authors:  A H Palamakumbura; S R Vora; M A Nugent; K H Kirsch; G E Sonenshein; P C Trackman
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

7.  Sucrose octasulfate regulates fibroblast growth factor-2 binding, transport, and activity: potential for regulation of tumor growth.

Authors:  Michael Fannon; Kimberly Forsten-Williams; Matthew A Nugent; Kalvin J Gregory; Chia Lin Chu; Adrienne L Goerges-Wildt; Dipak Panigrahy; Arja Kaipainen; Carmen Barnes; Cathy Lapp; Yuen Shing
Journal:  J Cell Physiol       Date:  2008-05       Impact factor: 6.384

8.  Dose-dependent response of FGF-2 for lymphangiogenesis.

Authors:  Lynn K Chang; Guillermo Garcia-Cardeña; Filip Farnebo; Michael Fannon; Emy J Chen; Catherine Butterfield; Marsha A Moses; Richard C Mulligan; Judah Folkman; Arja Kaipainen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

9.  Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.

Authors:  B Sharma; M Handler; I Eichstetter; J M Whitelock; M A Nugent; R V Iozzo
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

10.  Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.

Authors:  Malgorzata Zakrzewska; Antoni Wiedlocha; Anna Szlachcic; Daniel Krowarsch; Jacek Otlewski; Sjur Olsnes
Journal:  J Biol Chem       Date:  2009-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.